|
|
Market Analysis Reports of TREM2 agonist-2
|
Metabolic Syndrome Market Forecasts to 2032 – Global Analysis By Component (Obesity, Hypertension, Insulin Resistance & Hyperglycemia, and Dyslipidemia), Treatment Type, Diagnostic Method, Technology, End User and By Geography
... VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical ...
Biologics & Biosimilars Market Forecasts to 2032 – Global Analysis By Product Type (Biologics, Biosimilars), Therapeutic Area (Oncology, Ophthalmology, Autoimmune Disorders, Cardiovascular, Endocrinology, Infectious Diseases, Hematology, and Wound Healing & Regenerative Care), Manufacturing Source, Distribution Channel, End User, and By Geography
... VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical ...
Dengue Vaccine Market Forecasts to 2032 – Global Analysis By Product (Dengvaxia, Qdenga, and Other Pipeline Candidates), Vaccine Type, Treatment Adjuncts, Route of Administration, Distribution Channel, End User, and By Geography
... VG-3927, a novel, oral, small-molecule TREM2 agonist, which will be evaluated in a phase 2 clinical ...
|
|
|
|
